A Library of Potent TCRs Derived from Healthy Donors Targeting Kras G12d and G12v Neoantigens

Abstract Kirsten rat sarcoma (KRAS), the most frequently altered oncogene, is a key target for T cell-based therapies. Mutant KRAS (mKRAS)-specific T cell receptors (TCRs) enable targeted treatment for patients with matching mKRAS/HLA allele pairs. We generated a TCR warehouse library covering approximately one-quarter of pancreatic ductal adenocarcinoma patients and 10% of colorectal cancer patients. Warehouse TCRs exhibit strong avidities and cytotoxicity, comparable to existing benchmark TCRs. Detailed characterization of each TCR revealed unique biology for specific KRAS neoantigens. TCRs with high sensitivity for KRAS G12V/HLA-C*01:02 also recognize the wild-type epitope. However, the wild-type epitope abundance appears to be significantly lower, potentially creating a therapeutic window, albeit necessitating deeper evaluation. Additionally, we show that TCRs recognize KRAS G12V on HLA-C*03:03 and HLA-C*03:04 interchangeably, thereby resulting in a single neoantigen with one of the highest frequencies. In summary, this mKRAS-targeted TCR library comprises candidates for further preclinical and clinical development.

Authors

Institutions

Publication Details

Journal
Cancer Immunology Research
Published
2026-11-10
DOI
https://doi.org/10.1158/2326-6066.cir-26-0724
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A Library of Potent TCRs Derived from Healthy Donors Targeting Kras G12d and G12v Neoantigens

Vikram R. Juneja, Marit M. van Buuren, Sebastian Newrzela, Jared L. Dietze et al.
Cancer Immunology Research
CAR-T cell therapy research
article

A Library of Potent TCRs Derived from Healthy Donors Targeting Kras G12d and G12v Neoantigens

Vikram R. Juneja, Marit M. van Buuren, Sebastian Newrzela, Jared L. Dietze, Gavin M. Palowitch, Kendra C. Foley, Charles L. Dulberger, Christian Yee, Hannah I. Miller, Richard B. Gaynor, John R. Srouji, Tejashri Jadhav, Maria Massaro, Margaret M. Blythe
article en

Abstract

Abstract Kirsten rat sarcoma (KRAS), the most frequently altered oncogene, is a key target for T cell-based therapies. Mutant KRAS (mKRAS)-specific T cell receptors (TCRs) enable targeted treatment for patients with matching mKRAS/HLA allele pairs. We generated a TCR warehouse library covering approximately one-quarter of pancreatic ductal adenocarcinoma patients and 10% of colorectal cancer patients. Warehouse TCRs exhibit strong avidities and cytotoxicity, comparable to existing benchmark TCRs. Detailed characterization of each TCR revealed unique biology for specific KRAS neoantigens. TCRs with high sensitivity for KRAS G12V/HLA-C*01:02 also recognize the wild-type epitope. However, the wild-type epitope abundance appears to be significantly lower, potentially creating a therapeutic window, albeit necessitating deeper evaluation. Additionally, we show that TCRs recognize KRAS G12V on HLA-C*03:03 and HLA-C*03:04 interchangeably, thereby resulting in a single neoantigen with one of the highest frequencies. In summary, this mKRAS-targeted TCR library comprises candidates for further preclinical and clinical development.

Cancer Immunology Research
BioNTech (Germany) (DE), BioNTech (United States) (US)
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon